Clinical Trial Update: A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease [Phase 3]

View source ↗

Summary

Phase 3 safety study of a budesonide/glycopyrronium/formoterol fumarate combination with a next-generation propellant in adults with moderate to very severe chr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Budesonide/Glycopyrronium/Formoterol Fumarate (Budesonide/glycopyrronium/formoterol fumarate)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2025-09-19